Specifically, Glenmark challenged Merck's basic compound patent, RE 37,721 (the 721 patent) on numerous grounds.

Under the agreement, Glenmark will be able to launch their product on December 12, 2016 or earlier under certain circumstances, ahead of the April 25, 2017 expiration of Merck's patent exclusivity for Zetia.

This settlement effectively ends the lawsuit that was scheduled to begin on May 12, 2010, involving a challenge by Glenmark which sought to launch a generic version of Zetia before the April 2017 expiration of the patent exclusivity covering Zetia.

Will the settlement benefit Merck?

Have your say and discuss with your peers on the InfoGrok community.

Participate by posting your comments now.